VRTX · CUSIP 92532F100
Vertex Pharmaceuticals
Reported by 2 of 79 curated managers in Q2 2026, in the holdings snapshot last exported 2026-10-26.
- Managers holding
- 2
- Average portfolio weight
- 1.3%
- Combined reported value
- $27.5M
- Research group
- 79
2 of the 79 superinvestors Shameless Cloning tracks reported Vertex Pharmaceuticals (VRTX) in their Q2 2026 13F filings, worth $27.5M combined, at an average 1.3% of their portfolios. The largest positions by portfolio weight belong to Tweedy Browne (1.5%), Torray Funds (1.0%).
Reporting managers
This is a historical 13F snapshot, not a live shareholder register. The count covers all matched managers; dashboard rankings use only those with at least 95% coverage. Reported value is measured at filing quarter-end, not at today's price.
| Manager / SEC filer | % of portfolio | Reported value |
|---|---|---|
| Tweedy BrowneTweedy, Browne Co LLC | 1.5% | $19.9M |
| Torray FundsTorray Investment Partners LLC | 1.0% | $7.6M |